Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582759 · ClinicalTrials.gov registry record · NA
Sleep Hygiene Education, ReadiWatchTM Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia Effect, on Symptom Relief for Men With Prostate Cancer Receiving Androgen Deprivation Therapy
A NA study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT05582759 is a NA study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT05582759, a NA study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
Many treatments for prostate cancer can cause significant fatigue and/or problems with memory and concentration. Many treatments for prostate cancer also result in disturbed sleep. Improving sleep may reduce feelings of fatigue and improve memory and concentration. The purpose of this study is to test a wearable device that provides real-time feedback on sleep patterns, instruction on how to improve sleep, and a score that indicates periods of time when fatigue and issues with memory and concentration may be most troublesome. The study also is designed to test a type of treatment (cognitive behavioral therapy for insomnia, CBT-I) that is helpful for people who are experiencing disturbed sleep.
Interventions
- BEHAVIORAL teleCBT-I + SH/ReadiWatchTM
- BEHAVIORAL SH/ReadiWatchTM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2023-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582759
The ClinicalTrials.gov registry entry for NCT05582759 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which teleCBT-I + SH/ReadiWatchTM is the first listed.
NCT05582759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05582759 about?
NCT05582759 is a clinical study titled "Sleep Hygiene Education, ReadiWatchTM Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia Effect, on Symptom Relief for Men With Prostate Cancer Receiving Androgen Deprivation Therapy". Many treatments for prostate cancer can cause significant fatigue and/or problems with memory and concentration. Many treatments for prostate cancer also result in disturbed sleep. Improving sleep may reduce feelings of fatigue and improve memory and concentration. The purpose of this study is to te...
What is the current status of trial NCT05582759?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2022-10-24. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05582759?
The interventions under investigation include: teleCBT-I + SH/ReadiWatchTM (BEHAVIORAL), SH/ReadiWatchTM (BEHAVIORAL).
Who is sponsoring clinical trial NCT05582759?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.